Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Current Leases: 2014-2024

Historic Current Leases for Zevra Therapeutics (ZVRA) over the last 9 years, with Dec 2024 value amounting to $420,000.

  • Zevra Therapeutics' Current Leases fell 18.33% to $441,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $441,000, marking a year-over-year decrease of 18.33%. This contributed to the annual value of $420,000 for FY2024, which is 22.65% down from last year.
  • Per Zevra Therapeutics' latest filing, its Current Leases stood at $420,000 for FY2024, which was down 22.65% from $543,000 recorded in FY2023.
  • Over the past 5 years, Zevra Therapeutics' Current Leases peaked at $543,000 during FY2023, and registered a low of $327,000 during FY2020.
  • For the 3-year period, Zevra Therapeutics' Current Leases averaged around $481,000, with its median value being $480,000 (2022).
  • Its Current Leases has fluctuated over the past 5 years, first surged by 34.83% in 2022, then decreased by 22.65% in 2024.
  • Yearly analysis of 5 years shows Zevra Therapeutics' Current Leases stood at $327,000 in 2020, then climbed by 8.87% to $356,000 in 2021, then soared by 34.83% to $480,000 in 2022, then increased by 13.13% to $543,000 in 2023, then fell by 22.65% to $420,000 in 2024.